Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Meiji Completes New Facilities to Restart Domestic Production of 6-APA
October 20, 2025
- Chiesi Japan to Expand Workforce Tenfold by 2030 on Back of New Drug Filings
October 20, 2025
- iPark, KoreaBIO Ink MOU to Fuel Japan-Korea Cooperation in Life Sciences
October 20, 2025
- Novo, JAST Join Hands to Raise Awareness of Obesity
October 20, 2025
- Taiho Bags Haihe’s PI3Kα Inhibitor Risovalisib
October 17, 2025
- Lilly Japan Teams Up with 23 Medical Societies to Strengthen Obesity Care
October 17, 2025
- Viatris Snaps Up Japan’s Aculys Pharma, Gains 2 CNS Assets
October 17, 2025
- Organon Bids Farewell to 1990s Blockbusters Lipovas and Renivace in Japan
October 16, 2025
- ASKA Keeps Defense Policy in Place as Dalton Dispute Persists
October 15, 2025
- Sanofi, NIID Sign MOU on Infectious Disease Collaboration
October 15, 2025
- Astellas’ Vyloy Combo Fails to Improve Survival in PII Pancreatic Cancer Study
October 15, 2025
- Mitsubishi Tanabe Files Uplizna Label Expansion for gMG in Japan
October 15, 2025
- Novo, Sumitomo Extend Co-Promotion Partnership to Wegovy
October 15, 2025
- Kite Looks to Expand Japan CAR-T Footprint, Boosts Supply Infrastructure
October 15, 2025
- Moderna Launches LP.8.1-Adapted Spikevax for Ages 6 Months to 11 Years
October 15, 2025
- Chugai to Develop Roche’s GLP-1/GIP Agent CT-388 in Japan
October 14, 2025
- JT, Torii File Tapinarof Cream for Pediatric Atopic Dermatitis in Japan
October 14, 2025
- Eisai Maps Out 3-Pronged Strategy to Promote Leqembi: COO Naito
October 10, 2025
- NANO MRNA to Launch Investment Arm, Set Up Fund with SBI to Acquire Unlisted Biotechs
October 10, 2025
- Japan’s Medical and Pharma DX Market to Reach 1.35 Trillion Yen in 2035: Fuji Keizai
October 10, 2025
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…